Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab

Cadonilimab is the first bi-specific antibody approved for certain malignancies in June 2022, which has a modified Fc structure to reduce immune-related adverse events. To date, no reports have described Cadonilimab-related toxic epidermal necrolysis (TEN). Here, we report the first case of TEN-like...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1188523
Main Authors Chen, Peng-Yu, Li, Zi-Yun, Cai, Sui-Qing
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 03.08.2023
Subjects
Adalimumab
Adalimumab - therapeutic use
Antibodies, Bispecific - adverse effects
Antibodies, Bispecific - therapeutic use
Cadonilimab/AK104
Carcinoma, Hepatocellular - drug therapy
case report
Humans
immune checkpoint inhibitor
Immune Checkpoint Inhibitors - adverse effects
Immune Checkpoint Inhibitors - therapeutic use
immune-related adverse events
Immunology
Liver Neoplasms - drug therapy
Male
Middle Aged
Stevens-Johnson Syndrome - drug therapy
Stevens-Johnson Syndrome - etiology
toxic epidermal necrolysis
Treatment Outcome
Withholding Treatment
Cadonilimab/AK104
case report
immune checkpoint inhibitor
Adalimumab
immune-related adverse events
toxic epidermal necrolysis
Online AccessGet full text

Cover

More Information
Summary:Cadonilimab is the first bi-specific antibody approved for certain malignancies in June 2022, which has a modified Fc structure to reduce immune-related adverse events. To date, no reports have described Cadonilimab-related toxic epidermal necrolysis (TEN). Here, we report the first case of TEN-like reactions occurring during the treatment of hepatocellular carcinoma with Cadonilimab in combination with Lenvatinib and transarterial chemoembolization, successfully treated with supplemental Adalimumab. We confirmed Cadonilimab as the culprit and observed significant improvement in the patient’s condition following Adalimumab treatment. The case emphasizes the potential risk of Cadonilimab inducing TEN, and suggests that supplemental Adalimumab could be a favorable option for treating refractory Cadonilimab-related TEN.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
These authors have contributed equally to this work and share first authorship
Edited by: Mauro Alaibac, University of Padua, Italy
Reviewed by: Tibor Bakacs, Alfred Renyi Institute of Mathematics, Hungary; Tomoya Watanabe, Yokohama City University, Japan; Raghwendra Mishra, Ananda Mohan College, India
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1188523